Genesis Therapeutics
4:15 PM - 4:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Genesis Therapeutics has created the industry's most advanced molecular AI platform by combining physics-aware deep neural networks, new molecular simulation methods, and a massively scalable molecular generation engine. The company’s small molecule AI platform is uniquely able to address previously undruggable and data-poor targets, enabling immense swaths of chemical space to be searched.
Genesis is building an internal pipeline in oncology, and currently has 4 preclinical programs against high value targets. Genesis additionally announced a $20M upfront, $670M deal with Eli Lilly in April 2022 (for collaboration on three initial targets; Lilly has the option to nominate two more targets for an additional nomination payment per target). Genesis also has a discovery collaboration with Genentech (started in 2020), and raised a $52M Series A in 2020 with top tier investors including a16z, Rock Springs and T Rowe Price.
Genesis is building an internal pipeline in oncology, and currently has 4 preclinical programs against high value targets. Genesis additionally announced a $20M upfront, $670M deal with Eli Lilly in April 2022 (for collaboration on three initial targets; Lilly has the option to nominate two more targets for an additional nomination payment per target). Genesis also has a discovery collaboration with Genentech (started in 2020), and raised a $52M Series A in 2020 with top tier investors including a16z, Rock Springs and T Rowe Price.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Preclinical small molecule targeted oncology program (solid tumors, recently declared development candidate).
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
